Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | BCL9 | O00512 | 1/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40213 | 0.96 | HTR2A (0.53) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL1104745 | 0.96 | HTR2A (0.53) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL23044637 | 0.96 | HTR2A (0.53) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL12082016 | 0.96 | HTR2A (0.53) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL30233044 | 0.96 | HTR2A (0.53) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL409598 | 0.92 | HTR2A (0.59) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL9910888 | 0.91 | HTR2A (0.54) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL14876975 | 0.91 | HTR2A (0.54) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL4433836 | 0.88 | HTR2A (0.56) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL125510 | 0.88 | HTR2A (0.56) | HTR2ABCL9CTNNB1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115161728-B | Pore-forming agent for pore metallization, preparation method and application | 南通赛可特电子有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-115161728-A | Pore-finishing agent for pore metallization, preparation method and application | 南通赛可特电子有限公司 | 2022-10-11 | — | — | CN | claimed |
| US-20150297681-A1 | Pegylated Insulin Lispro Compounds | ELI LILLY AND COMPANY (US) | 2015-10-22 | — | — | US | claimed |
| EP-2288375-B1 | PEGYLATED INSULIN LISPRO COMPOUNDS | LILLY CO ELI (US) | 2012-04-25 | — | — | EP | claimed |
| JP-2011524357-A | — | — | 2011-09-01 | — | — | JP | claimed |
| US-20110105392-A1 | Pegylated Insulin Lispro Compounds | ELI LILLY AND COMPANY (US) | 2011-05-05 | — | — | US | claimed |
| EP-2288375-A1 | PEGYLATED INSULIN LISPRO COMPOUNDS | ELI LILLY AND COMPANY (US) | 2011-03-02 | — | — | EP | claimed |
| US-20090312236-A1 | PEGYLATED INSULIN LISPRO COMPOUNDS | ELI LILLY AND COMPANY | 2009-12-17 | — | — | US | claimed |
| WO-2009152128-A1 | PEGYLATED INSULIN LISPRO COMPOUNDS | ELI LILLY AND COMPANY (US) | 2009-12-17 | — | — | WO | claimed |
| WO-2024259930-A9 | PHOSPHONATE COMPOUND AND MEDICAL USE THEREOF | 润佳（苏州）医药科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| WO-2024259930-A1 | PHOSPHONATE COMPOUND AND MEDICAL USE THEREOF | 润佳（苏州）医药科技有限公司 | 2024-12-26 | — | — | WO | disclosed |
| CN-117285566-A | Phosphonate compound and medical application thereof | 润佳（苏州）医药科技有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-112442011-B | Prodrug compound and application thereof in treating cancers | 润佳（苏州）医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| EP-1421175-A2 | POLYMER STABILIZED PROTEINASES | Mountain View Pharmaceuticals, Inc. (US) | 2004-05-26 | — | — | EP | disclosed |
| WO-2004002985-A1 | PEPTIDIC THROMBIN INHIBITOR COMPOUND | LG LIFE SCIENCES LTD. (KR) | 2004-01-08 | — | — | WO | disclosed |
| US-20030012777-A1 | Polymer conjugates of proteinases | MOUNTAIN VIEW PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| WO-2003002716-A2 | POLYMER STABILIZED PROTEINASES | MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) | 2003-01-09 | — | — | WO | disclosed |
| US-6291432-B1 | (R)-N-(2-METHYLBENZYL)-3-((2S, 3S)-3-(N-(2-CHROMONECARBONYL)-L-ASPARAGINYL)AMINO-2-HYDROXY-4-PHENYLBUTANO YL)-5,5-DIMETHYL-1,3-THIAZOLIDINE-4-CARBOXAMIDE CAN BE GIVEN AS A TYPICAL EXAMPLE OF THIS COMPOUND. | JAPAN ENERGY CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0900566-A1 | NOVEL TRIPEPTIDE COMPOUNDS AND ANTI-AIDS DRUGS | JAPAN ENERGY CORPORATION (JP) | 1999-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105392-A1 | Pegylated Insulin Lispro Compounds | IAPP, IDE, LIPE | HTR2A 3212/4885BCL9 4361/4885CTNNB1 4877/4885 |
| US-20090312236-A1 | PEGYLATED INSULIN LISPRO COMPOUNDS | IAPP, IDE, LIPE | HTR2A 3212/4885BCL9 4361/4885CTNNB1 4877/4885 |
| US-20150297681-A1 | Pegylated Insulin Lispro Compounds | IAPP, IDE, LIPE | HTR2A 3212/4885BCL9 4361/4885CTNNB1 4877/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | HTR2A 4484/4885BCL9 628/4885CTNNB1 509/4885 |
| US-20030012777-A1 | Polymer conjugates of proteinases | PRNP, PRSS3, PRSS1 | HTR2A 4693/4885BCL9 3968/4885CTNNB1 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.